Synthetic cannabidiol - INSYS Therapeutics

Drug Profile

Synthetic cannabidiol - INSYS Therapeutics

Alternative Names: Pharmaceutical cannabidiol (CBD) - INSYS Therapeutics

Latest Information Update: 03 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Developer California Pacific Medical Center; INSYS Therapeutics, Inc; The University of Montreal Hospital Research Center; University of Chicago
  • Class Analgesics; Antiepileptic drugs; Antipsoriatics; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Heart failure therapies; Muscle relaxants; Neuroprotectants; Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Serotonin 1 receptor modulators; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome; Lennox-Gastaut syndrome; Infantile spasms; Glioblastoma; Glioma; Schizophrenia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dravet syndrome; Drug abuse; Infantile spasms; Lennox-Gastaut syndrome
  • Phase II Epilepsy; Prader-Willi syndrome
  • Phase I/II Pain
  • Preclinical Glioblastoma; Peripheral nervous system diseases

Most Recent Events

  • 26 Apr 2018 INSYS therapeutics and University of California San Diego Center for Medicinal Cannabis Research plans a clinical trial (In children) for Epilepsy in 2019
  • 14 Mar 2018 INSYS Therapeutics plans a phase II trial for Prader-Willi syndrome (In children, In adolescents) in June 2018 (NCT03458416)
  • 05 Mar 2018 Phase-III clinical trials in Infantile spasms in USA (In children, In infants, Adjunctive treatment) (PO) (NCT03421496)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top